Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$318.46
pos +0.00
+0.00%
Today's Range: 311.30 - 319.34 | BIIB Avg Daily Volume: 1,230,000
Last Update: 09/22/17 - 4:00 PM EDT
Volume: 0
YTD Performance: 21.86%
Open: $0.00
Previous Close: $315.03
52 Week Range: $244.28 - $330.00
Oustanding Shares: 211,431,746
Market Cap: 66,607,342,942
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 10
Moderate Buy 0 0 0 0
Hold 10 8 7 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.05 1.94 1.88 1.75
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 20.67
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
20.67 18.60 36.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
13.50% 9.77% 4.79%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
EBITDA 4.28B
Revenue 10.13B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $5.62 $5.56 $21.42 $23.15
Number of Analysts 23 23 23 24
High Estimate $6.16 $6.05 $22.32 $25.89
Low Estimate $5.10 $4.85 $20.77 $20.54
Prior Year $5.19 $5.04 $20.22 $21.42
Growth Rate (Year over Year) 8.32% 10.31% 5.95% 8.04%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Update
Sep 15, 2017 | 7:12 AM EDT
Biogen stock coverage was initiated at RBC with a "Sector Perform" rating and a $319 price target.
Today's breakout move in the stock is a highlight of the surging sector.
Today's breakout move in the stock is a highlight of the surging sector.
Bullish
Aug 16, 2017 | 9:09 AM EDT
Biogen was added to Goldman Sachs Conviction Buy list and assigned a $338 price target.
Bullish
Jul 26, 2017 | 9:07 AM EDT
Goldman Sachs upgraded Biogen to "Buy" from "Neutral" with a $338 price target.
These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.

Biogen Ready for a Big Bounce Real Money Pro($)

The chart shows this stock has bottomed.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
The market rally broadened out nicely today.

Charting the Biotechs Real Money Pro($)

Time to revisit some stocks now that biotech has cooled.

Columnist Conversations

Spent a good amount of time with PayPal CEO Dan Schulman this week...and came away fully understanding why thi...
Has quietly taken a mini beating over the past few weeks. Might be worth a look on Monday given everything tha...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.